Matinas BioPharma Announces Two Upcoming Data Presentations of Lead Product Candidate MAT2203 at The American Society for Mic...
May 30 2017 - 08:05AM
– NIH investigators to present interim data from
the collaborative Phase 2a clinical study of MAT2203 for the
treatment of chronic refractory mucocutaneous candidiasis –
Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage
biopharmaceutical company focused on developing innovative
anti-infectives for orphan indications, announced today that two
abstracts will be presented in poster sessions at The American
Society for Microbiology’s (ASM Microbe/ICAAC 2017) scientific
meeting being held June 1–5 at the Ernest N. Morial
Convention Center in New Orleans, LA.
Details of the MAT2203 presentations are as
follows:
Raphael Mannino, Ph.D., Chief Scientific Officer
of Matinas, will present the abstract titled, “Efficacy of Oral
Encochleated Amphotericin B (CAMB) in a Mouse Model of Cryptococcal
Meningeoencephalitis.”
Poster: |
|
189 |
Date: |
|
Friday, June 2nd |
Time: |
|
12:45 p.m. – 2:45 p.m.
CDT |
Location: |
|
Exhibit Hall D, Exhibit
and Poster Hall 041 |
Session: |
|
Antimicrobial
Pharmacokinetics: Antifungal PK/PD Studies |
Alexandra Freeman, M.D., of the National
Institute of Allergy and Infectious Diseases (NIAID) Laboratory of
Clinical Infectious Diseases, Principal Investigator of the Phase
2a study sponsored by Matinas BioPharma, will present the abstract
titled, “Oral Encochleated Amphotericin B (CAMB) in the Treatment
of Chronic Azole Resistant Mucocutaneous Candidiasis.”
This presentation will be a summary of interim
results from the ongoing open-label, NIH-sponsored Phase 2a
clinical study of MAT2203 in immunocompromised patients.
Poster: |
|
240 |
Date: |
|
Saturday, June 3rd |
Time: |
|
12:15 p.m. – 2:15 p.m.
CDT |
Location: |
|
Exhibit Hall D, Exhibit
and Poster Hall 195 |
Session: |
|
Mycology: New
Antifungal Agents I |
About MAT2203
MAT2203 is an orally-administered, encochleated
formulation of amphotericin B (a broad spectrum fungicidal agent).
Little to no clinical resistance has been reported to date with
amphotericin B as compared to the rapidly emerging drug resistance
seen in other antifungal therapies. Currently, IV-only administered
amphotericin B is the only broad spectrum fungicidal available but
its IV-delivery results in significant treatment-limiting side
effects, including nephrotoxicity. The ability to provide
amphotericin B orally using our proprietary and novel oral
formulation may offer a new and promising alternative for patients
and doctors. Currently, there are two Phase 2 studies underway with
MAT2203. The first is an open-label Phase 2a
NIH/NIAID-sponsored clinical study with MAT2203 in
immunocompromised patients with refractory mucocutaneous
candidiasis. The second is a Phase 2 study of MAT2203 in patients
with vulvovaginal candidiasis (VVC). Data from both studies is
expected to be announced in June of 2017. The FDA has
designated MAT2203 as a Qualified Infectious Disease Product (QIDP)
for the treatment of invasive candidiasis and the treatment of
aspergillosis, as well as for the prevention of invasive fungal
infections due to immunosuppressive therapy. MAT2203 is also being
explored for treatment of additional anti-fungal indications and
may have the potential for Orphan Drug Designation in certain of
these indications.
About Matinas BioPharma
Matinas BioPharma is a clinical-stage
biopharmaceutical company focused on developing innovative
anti-infectives for orphan indications. The Company's proprietary,
disruptive technology utilizes lipid-crystal nano-particle
cochleates to nano-encapsulate existing drugs, making them safer,
more tolerable, less toxic and orally bioavailable.
The Company's lead anti-infective product
candidates, MAT2203 and MAT2501, position Matinas BioPharma to
become a leader in the safe and effective delivery of
anti-infective therapies utilizing its proprietary lipid-crystal
nano-particle cochleate formulation technology. For more
information, please visit www.matinasbiopharma.com and connect with
the Company on Twitter, LinkedIn, Facebook, and Google+.
Forward Looking Statements:
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
including those relating to the Company's strategic focus and the
future development of its product candidates, including MAT2203 and
MAT2501, the anticipated timing of regulatory submissions, the
anticipated timing of clinical studies, the Company’s ability to
identify and pursue development and partnership opportunities for
its products or platform delivery technology on favorable terms, if
at all, and the ability to obtain required regulatory approval and
other statements that are predictive in nature, that depend upon or
refer to future events or conditions. All statements other than
statements of historical fact are statements that could be
forward-looking statements. Forward-looking statements include
words such as "expects," "anticipates," "intends," "plans,"
"could," "believes," "estimates" and similar expressions. These
statements involve known and unknown risks, uncertainties and other
factors which may cause actual results to be materially different
from any future results expressed or implied by the forward-looking
statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, our ability
to obtain additional capital to meet our liquidity needs on
acceptable terms, or at all, including the additional capital which
will be necessary to complete the clinical trials of our product
candidates; our ability to successfully complete research and
further development and commercialization of our product
candidates; the uncertainties inherent in clinical testing; the
timing, cost and uncertainty of obtaining regulatory approvals; our
ability to maintain and derive benefit from the Qualified
Infectious Disease Product (QIDP), Orphan and/or Fast Track
designations for MAT2203 and MAT2501, which does not change the
standards for regulatory approval or guarantee regulatory approval
on an expedited basis, or at all; our ability to protect the
Company's intellectual property; the loss of any executive officers
or key personnel or consultants; competition; changes in the
regulatory landscape or the imposition of regulations that affect
the Company's products; and the other factors listed under "Risk
Factors" in our filings with the SEC, including Forms 10-K, 10-Q
and 8-K. Investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of
this release. Except as may be required by law, the Company does
not undertake any obligation to release publicly any revisions to
such forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated
events. Matinas BioPharma's product candidates are all in a
development stage and are not available for sale or use.
Investor Contact
Jenene Thomas
Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475
Email: jenene@jenenethomascommunications.com